AEON Biopharma financials
$0.2590−0.99%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$12.8M | $73.0M | -$348.1M |
| Net income | -$39.2M | $42.0M | -$384.6M |
| Net margin | — | — | — |
| Diluted EPS | $-3.95 | $72.93 | $-745.20 |
| EBITDA | -$12.7M | $73.1M | -$348.0M |
| Operating cash flow | -$17.3M | -$20.3M | -$47.8M |
| Free cash flow | -$17.3M | -$20.3M | -$47.8M |
| Diluted shares | 9.9M | 0.6M | 0.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $3.0M | $13.0K | $5.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $36.0M | $15.3M | $0.00 |
| Total assets | $5.6M | $3.1M | $6.8M |
| Total liabilities | $60.6M | $31.7M | $159.9M |
| Shareholders' equity | -$55.0M | -$28.6M | -$153.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology